Amneal Pharmaceuticals vs Indivior
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Amneal Pharmaceuticals and Indivior side by side, using each oneβs latest annual report. Here is what stands out:
- Amneal Pharmaceuticals is the larger business, with $3.0B of revenue in fiscal 2025 against $1.2B for Indivior, about 2.4 times as much.
- Amneal Pharmaceuticals grew revenue faster (8.1%, against 4.3%).
- Indivior kept more of each dollar of sales as operating profit (21.2% operating margin, against 13.1%).
- Amneal Pharmaceuticals turned more of its sales into free cash flow (8.9% FCF margin, against β7.5%).
- Investors pay more for each dollar of Amneal Pharmaceuticalsβs earnings: a P/E of 42.9x against 12.4x for Indivior.
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Amneal Pharmaceuticals
AMRX
3/8
Revenue growthFCF marginPiotroski F-score
Indivior
INDV
5/8
Gross marginOperating marginNet marginNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | AMRX FY25 | INDV FY25 |
|---|---|---|
| Size | ||
| Market cap | $6.9B | $4.3B |
| Revenue | $3.0B | $1.2B |
| Free cash flow | $270M | β$93.0M |
| Net income | $72.1M | $210M |
| Growth | ||
| Revenue growth | 8.1% | 4.3% |
| 5-year growth | 8.7% | β |
| Share count change | 5.1% | β3.8% |
| Profitability | ||
| Gross margin | 36.9% | 80.2% |
| Operating margin | 13.1% | 21.2% |
| Net margin | 2.4% | 17.0% |
| FCF margin | 8.9% | β7.5% |
| Return on capital | 16.1% | β |
| Return on equity | β | β |
| Balance sheet | ||
| Net debt | $2.3B | $124M |
| Net debt / EBITDA | 3.8x | 0.5x |
| Dividends and buybacks | $0.0M | $11.0M |
| Valuation & quality | ||
| P/E | 42.9x | 12.4x |
| Piotroski F-score | 7 | 4 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.